Pacira BioSciences' Accumulated Expenses rose 4.28% to $79.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.6 million, marking a year-over-year increase of 4.28%. This contributed to the annual value of $80.1 million for FY2024, which is 24.72% up from last year.
Pacira BioSciences' Accumulated Expenses amounted to $80.1 million in FY2024, which was up 24.72% from $64.2 million recorded in FY2023.
In the past 5 years, Pacira BioSciences' Accumulated Expenses registered a high of $127.6 million during FY2021, and its lowest value of $64.2 million during FY2023.
Its 3-year average for Accumulated Expenses is $78.1 million, with a median of $80.1 million in 2024.
Per our database at Business Quant, Pacira BioSciences' Accumulated Expenses surged by 79.72% in 2021 and then fell by 29.61% in 2022.
MRY analysis of 5 years shows Pacira BioSciences' Accumulated Expenses stood at $71.0 million in 2020, then skyrocketed by 79.72% to $127.6 million in 2021, then dropped by 29.61% to $89.8 million in 2022, then decreased by 28.45% to $64.2 million in 2023, then increased by 24.72% to $80.1 million in 2024.
Its Accumulated Expenses stands at $80.1 million for FY2024, versus $64.2 million for FY2023 and $89.8 million for FY2022.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value